A Velescu1, A Clara2, J Peñafiel3, R Ramos4, R Marti5, M Grau3, I R Dégano3, J Marrugat3, R Elosua6. 1. Angiology and Vascular Surgery Department, Hospital del Mar, Barcelona, Spain; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Universitat Autònoma de Barcelona, Spain. 2. Angiology and Vascular Surgery Department, Hospital del Mar, Barcelona, Spain; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. 3. IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. 4. Research Unit, Family Medicine, Girona, Spain; Jordi Gol Institute for Primary Care Research (IDIAP Jordi Gol), Girona, Spain; TransLab Research Group, Department of Medical Sciences, School of Medicine, University of Girona, Girona, Spain. 5. Universitat Autònoma de Barcelona, Spain; Research Unit, Family Medicine, Girona, Spain. 6. IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. Electronic address: relosua@imim.es.
Abstract
OBJECTIVES: Cardiovascular risk estimation is a key element of current primary prevention strategies, despite its limited accuracy. Several biomarkers are being tested to assess their capacity to improve coronary (CHD) and cardiovascular (CVD) prediction. One of these biomarkers is ankle brachial index (ABI). The aim of this study was to assess whether the inclusion of ABI improved the predictive capacity of the Framingham-REGICOR risk function in an area of low CVD incidence. METHODS: A total of 5248 individuals, aged 35-74 years, from a prospective population-based cohort study were followed up for a median 5.9 years. Baseline ABI was measured using a standardized method. All incident CHD (angina, myocardial infarction, coronary revascularization, CHD death) and CVD (also including fatal and non-fatal stroke) events were recorded. Improvements in discrimination (ΔC-statistics) and reclassification by net reclassification index (NRI) were assessed. RESULTS: During follow-up, 111 and 64 subjects presented with a coronary or cerebrovascular event. Pathological ABI (≤0.9) was associated with increased CHD and CVD risk (HR: 2.08 and HR: 2.24, respectively; p-value<0.001). Including ABI in the Framingham-REGICOR function improved both its discrimination and its reclassification capacity for CVD events but not for CHD events; the ΔC-statistic for CVD events was 0.007 (95% Confidence Interval: 0.001; 0.017) and the NRI was 0.029 (95% CI: 0.014-0.045; p-value<0.001). CONCLUSION: Inclusion of the ABI improves the predictive capacity of the Framingham-REGICOR risk function. The study results indicate the potential value of including this simple test in cardiovascular risk stratification and support current guidelines recommendations.
OBJECTIVES: Cardiovascular risk estimation is a key element of current primary prevention strategies, despite its limited accuracy. Several biomarkers are being tested to assess their capacity to improve coronary (CHD) and cardiovascular (CVD) prediction. One of these biomarkers is ankle brachial index (ABI). The aim of this study was to assess whether the inclusion of ABI improved the predictive capacity of the Framingham-REGICOR risk function in an area of low CVD incidence. METHODS: A total of 5248 individuals, aged 35-74 years, from a prospective population-based cohort study were followed up for a median 5.9 years. Baseline ABI was measured using a standardized method. All incident CHD (angina, myocardial infarction, coronary revascularization, CHD death) and CVD (also including fatal and non-fatal stroke) events were recorded. Improvements in discrimination (ΔC-statistics) and reclassification by net reclassification index (NRI) were assessed. RESULTS: During follow-up, 111 and 64 subjects presented with a coronary or cerebrovascular event. Pathological ABI (≤0.9) was associated with increased CHD and CVD risk (HR: 2.08 and HR: 2.24, respectively; p-value<0.001). Including ABI in the Framingham-REGICOR function improved both its discrimination and its reclassification capacity for CVD events but not for CHD events; the ΔC-statistic for CVD events was 0.007 (95% Confidence Interval: 0.001; 0.017) and the NRI was 0.029 (95% CI: 0.014-0.045; p-value<0.001). CONCLUSION: Inclusion of the ABI improves the predictive capacity of the Framingham-REGICOR risk function. The study results indicate the potential value of including this simple test in cardiovascular risk stratification and support current guidelines recommendations.
Authors: Josiemer Mattei; Daniela Sotres-Alvarez; Marc Gellman; Sheila F Castañeda; Frank B Hu; Katherine L Tucker; Anna Maria Siega-Riz; Robert C Kaplan Journal: Clin Nutr Date: 2017-06-08 Impact factor: 7.324
Authors: Oscar Campuzano; Olallo Sanchez-Molero; Anna Fernandez; Irene Mademont-Soler; Monica Coll; Alexandra Perez-Serra; Jesus Mates; Bernat Del Olmo; Ferran Pico; Laia Nogue-Navarro; Georgia Sarquella-Brugada; Anna Iglesias; Sergi Cesar; Esther Carro; Juan Carlos Borondo; Josep Brugada; Josep Castellà; Jordi Medallo; Ramon Brugada Journal: Sports Med Date: 2017-10 Impact factor: 11.136
Authors: M Teresa Alzamora; Rosa Forés; Guillem Pera; José Miguel Baena-Díez; Marta Valverde; Pere Torán Journal: PLoS One Date: 2019-01-23 Impact factor: 3.240
Authors: Christopher E Clark; Fiona C Warren; Kate Boddy; Sinead T J McDonagh; Sarah F Moore; John Goddard; Nigel Reed; Malcolm Turner; Maria Teresa Alzamora; Rafel Ramos Blanes; Shao-Yuan Chuang; Michael Criqui; Marie Dahl; Gunnar Engström; Raimund Erbel; Mark Espeland; Luigi Ferrucci; Maëlenn Guerchet; Andrew Hattersley; Carlos Lahoz; Robyn L McClelland; Mary M McDermott; Jackie Price; Henri E Stoffers; Ji-Guang Wang; Jan Westerink; James White; Lyne Cloutier; Rod S Taylor; Angela C Shore; Richard J McManus; Victor Aboyans; John L Campbell Journal: Hypertension Date: 2020-12-21 Impact factor: 10.190
Authors: Rosa Forés; Maria Teresa Alzamora; Guillem Pera; José Miguel Baena-Díez; Xavier Mundet-Tuduri; Pere Torán Journal: PLoS One Date: 2018-01-16 Impact factor: 3.240